ImmuPharma plc (LSE:IMM) fell 5.58% on 2 October 2026. The specialist drug discovery and development company focuses on peptide-based therapeutics, with two key assets: P140, an autoimmune technology platform, and Kapiglucagon, a treatment being developed for type 1 diabetes.
For a company whose share price trades at around one penny, timely delivery of audited accounts removes a key overhang. Last year, the audit of the 2025 accounts was not completed by the AIM deadline, which led to a short suspension of trading in …
Management has guided that the group should be profitable in the second half, so the forthcoming update will be a key test of that target.
SkinBioTherapeutics is an AIM-quoted life science company focused on skin health and the microbiome. It operates a products division, which includes Dermatonics topical skincare for barrier repair and foot health, and AxisBiotix, an oral supplement aimed at inflammatory skin conditions that has been stocked …
TSP Advanced Technologies, which changed its name from TruSpine Technologies in November 2025, is quoted on the Access segment of the Aquis Growth Market under the code TSP. It develops products for spinal fusion applications and has not yet generatedRevenuefrom operations. Geoff Miller chairs …
Faron is a clinical-stage biopharmaceutical company developing bexmarilimab, an antibody targeting the Clever-1 receptor, for blood cancers. Its shares trade on AIM in London under the code FARN and onNasdaqFirst North in Helsinki under FARON. Dr Juho Jalkanen is chief executive. The company reported …
Solvonis describes itself as a late clinical-stage biopharmaceutical company focused on central nervous system disorders and addiction. Its shares trade on the Main Market of theLondon Stock Exchangeunder the ticker SVNS. The pipeline is built around SVN-001, a ketamine-based treatment for severe alcohol use …
Futura Medical, quoted on AIM since 2003, develops sexual health products based on topically delivered gel formulations. Its lead product is Eroxon, a gel for erectile dysfunction, which is sold in the US through partners and earns royalties. Its pipeline includes Eroxon Intense, which …
The shares have had a volatile 12 months, trading in a 52-week range of roughly 1,300p to 3,020p, so the run-up to results is a period when buyers and sellers are particularly active.
CelLBxHealth's Parsortix platform captures circulating tumour cells, or CTCs, from a simple blood sample. These cells can reveal how a cancer is behaving and responding to treatment, making the technology valuable for research,Drug Developmentand clinical oncology.